Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1671 1672
This examiner grants 26% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17835751 | SELF-ASSEMBLING VIRAL SPIKE-EABR NANOPARTICLES | Final Rejection | California Institute of Technology |
| 17925920 | CORONAVIRUS ANTIGEN COMPOSITIONS AND THEIR USES | Non-Final OA | Flagship Pioneering Innovations VI, LLC |
| 17457594 | METHOD FOR DETECTION OF VIRAL INFECTIONS USING SPLIT ENZYMES | Non-Final OA | Brigham Young University |
| 17632733 | TRANSPLANT DIAGNOSTICS USING CRISPR-BASED TECHNOLOGY | Final Rejection | The Brigham and Women's Hospital, Inc. |
| 17696646 | METHOD FOR RAPID PREPARATION OF EPIDEMIC INFECTIOUS BRONCHITIS VACCINE | Final Rejection | SOUTH CHINA AGRICULTURAL UNIVERSITY |
| 17905614 | VACCINES AGAINST SARS-COV-2 AND OTHER CORONAVIRUSES | Non-Final OA | The Government of the United States, as Represented by the Secretary of the Army |
| 17720025 | Methods of Inducing Immune Response Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern | Final Rejection | Inovio Pharmaceuticals, Inc. |
| 17919096 | ADENOVIRUS IMMUNOASSAY METHOD AND IMMUNOASSAY INSTRUMENT | Non-Final OA | DENKA COMPANY LIMITED |
| 17906310 | PADLOCK PROBE-BASED ROLLING CIRCLE AMPLIFICATION PAIRED WITH NUCLEASE PROTECTION FOR POINT-OF-NEED NUCLEIC ACID DETECTION | Final Rejection | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION |
| 17631439 | TARGETED EXOSOME BASED ON RBD REGION OF SARS-COV-2 S PROTEIN AND PREPARATION METHOD THEREOF | Non-Final OA | SOOCHOW UNIVERSITY |
| 18011789 | METHOD FOR MASS-PRODUCING VACCINIA VIRUS BY USING SUSPENSION CELLS | Final Rejection | KOLON LIFE SCIENCE, INC. |
| 16976277 | EXOSOME TARGETING OF CD4+ EXPRESSING CELLS | Final Rejection | Rhode Island Hospital |
| 17607383 | ANTIBODIES AND METHODS FOR TREATMENT OF INFLUENZA A INFECTION | Non-Final OA | VIR BIOTECHNOLOGY, INC. |
| 18042083 | REAGENTS AND METHODS FOR PREVENTING, TREATING OR LIMITING SEVERE ACUTE RESPIRATORY SYNDROME (SARS) CORONAVIRUS INFECTION | Non-Final OA | PHYLEX BIOSCIENCES, INC. |
| 18020210 | COMPOSITIONS FOR TREATING GASTROINTESTINAL ADENOCARCINOMAS BY ALTERING THE TUMOR MICROENVIRONMENT | Final Rejection | Nordic Science Group ApS |
| 18005429 | ANTIGENS, ASSAYS, AND METHODS ASSOCIATED WITH SARS-COV-2 | Non-Final OA | KREUTZ, Fernando Thome |
| 18004148 | A DNA PLASMID SARS-CORONA VIRUS-2/COVID-19 VACCINE | Non-Final OA | STATENS SERUM INSTITUT |
| 17493103 | FUSION PROTEIN COMPRISING CIRCOVIRIDAE CAPSID PROTEIN, AND CHIMERIC VIRUS-LIKE PARTICLES COMPOSED THEREOF | Non-Final OA | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. |
| 17925766 | VIRUS STABILIZER, GELATIN HYDROLYSATE FOR VIRUS STABILIZER, AND VIRUS-CONTAINING COMPOSITION | Final Rejection | INCORPORATED EDUCATIONAL INSTITUTION RAKUNO GAKUEN |
| 17803699 | REPLICATION-COMPETENT CONTROLLED HERPESVIRUSES EXPRESSING A SARS COV-2 ANTIGEN | Final Rejection | HSF Pharmaceuticals SA |
| 17908221 | CORONAVIRUS VACCINES COMPRISING A TLR9 AGONIST | Non-Final OA | Dynavax Technologies Corporation |
| 17784016 | INFLUENZA ARRAYS AND USE THEREOF | Final Rejection | NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD. |
| 17835235 | FLAVIVIRUS ARRAYS AND USE THEREOF | Non-Final OA | NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD. |
| 17805396 | ORAL ADMINISTRATION OF CORONAVIRUS SPIKE PROTEIN FOR ALTERING CYTOKINE LEVELS AND PROVIDING PASSIVE IMMUNITY TO NEWBORN PIGS | Non-Final OA | MAZEN ANIMAL HEALTH INC. |
| 17602923 | RECOMBINANT CIRCOVIRUS CAPSID-VIRUS-LIKE PARTICLE (VLP): COMPOSITIONS, METHODS AND USES | Final Rejection | HUVEPHARMA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy